Peptides and preparations discussed in neurobiology are often grouped under outcome-led labels such as “nootropic,” “sleep peptide,” “anxiety peptide,” “stroke peptide,” or “longevity peptide.” Those labels can conceal differences in chemical identity and in what the experiments actually measured.
Semax, Selank, DSIP/emideltide, Cerebrolysin, and Epitalon differ in sequence or composition, study model, human evidence, reporting quality, and regulatory record. This hub explains those differences without ranking or recommending the substances. The laboratory, animal, and human evidence guide explains why findings cannot be treated as interchangeable across models.
This page is educational. It provides no medical advice, treatment recommendation, or dosing, preparation, administration, reconstitution, or self-use instructions. It does not authenticate a Serum Research catalog material or establish its quality, safety, or equivalence to a studied preparation.
Defined synthetic peptides
Semax
Semax has laboratory, animal, limited human, and surrogate-imaging research. A study of 52 healthy participants compared short-term functional-connectivity measurements after Semax, Selank, or placebo. Its reported imaging differences and post-hoc analyses do not establish improved cognition, mood, or clinical recovery.[4]
FDA’s May 11, 2026 memorandum for the July 23–24, 2026 advisory meeting distinguished Semax free base from acetate and described inconsistent substance naming. It found insufficient effectiveness evidence for the specific uses assessed: cerebral ischemia, migraine, and trigeminal neuralgia. Reporting limitations included unclear material identity and inadequate study or endpoint detail.[1] That dated advisory assessment is not drug approval or a final 503A-list determination.
Selank
The Selank literature includes different experiments that should not be flattened into one positive claim:
- In the IMR-32 cell-line study, Selank alone did not change expression in the tested 84-gene panel. Findings with GABA or olanzapine combinations were different; they do not convert the Selank-alone result into a positive finding.[11]
- The antenatal-hypoxia study used rats, not pregnant people or a human treatment population.[12]
- The cytokine report combined peripheral-blood-cell experiments with patient biomarker observations. Those measurements do not establish patient-centered clinical benefit.[13]
- An anxiety/neurasthenia report compared 30 participants receiving Selank with 32 receiving medazepam. The abstract reports similar symptom effects, but the comparison had no reported placebo arm and does not establish therapeutic equivalence.[14]
- Another report compared phenazepam alone in 30 participants with phenazepam plus Selank in 40. That is an add-on comparison: it can address an incremental effect under its study conditions, but not Selank monotherapy. The abstract does not describe allocation or blinding methods, so this hub does not treat the reported advantages as a robust causal or synergy finding.[15]
The healthy-participant connectivity experiment is also an imaging study, not an anxiety-treatment trial.[4] The two clinical-comparator abstracts do not provide enough information here to verify their allocation safeguards, endpoint hierarchy, multiplicity controls, or complete harms reporting.[14,15]
DSIP / emideltide
DSIP is a historical common name; FDA uses emideltide for this substance. The May 11, 2026 memorandum distinguishes its free-base and acetate forms.[2]
A double-blind, matched-pairs parallel-group insomnia study included 16 participants, eight in each group. It reported weak differences in selected objective sleep measures and no improvement in subjective sleep quality. The authors judged the short-term findings unlikely to provide major therapeutic benefit.[5] “Double-blind” and “matched pairs” are the reported design descriptions; they should not be expanded into an unverified randomization method.
FDA’s memorandum for the July 2026 meeting evaluated chronic insomnia, narcolepsy, and opioid withdrawal. Its insomnia assessment described the historical findings as inconclusive or preliminary, with limitations in control groups and clinical relevance. It also found safety inadequately characterized and noted important differences between the routes studied and the route proposed for compounding.[2] A small study with few reported adverse events cannot establish broad safety.
A complex biological preparation
Cerebrolysin
Cerebrolysin is a porcine-brain-derived mixture of low-molecular-weight peptides and amino acids, not one discrete peptide sequence.[6,7] Source material, process, composition, and comparability matter before results can be assumed to apply to another preparation.
The CASTA paper reports 1,070 participants: 529 assigned to Cerebrolysin and 541 to placebo. Its confirmatory primary assessment combined the modified Rankin Scale, Barthel Index, and NIH Stroke Scale at 90 days; it did not find a significant between-group difference. The severity-subgroup findings were post hoc and were described as needing confirmation, not as a successful primary result.[6]
The current NCT00868283 record is marked Completed and was last updated December 15, 2023. It lists 1,071 enrolled, rather than the paper’s 1,070, and names Ever Neuro Pharma GmbH as sponsor. No summary results or protocol/analysis-plan documents were posted in the registry record checked for this hub. The one-participant discrepancy is unresolved here; registry enrollment is not substituted for the paper’s reported participant count.[6,17]
A 2024 laboratory comparison reported differences in peptide fingerprints and a cell-based assay among sampled preparations. Its bioassay used a Cerebrolysin reference and was validated for that preparation, with one batch per tested product in the bioassay. These sample- and assay-specific findings are not a clinical comparison of efficacy or safety and do not authenticate a catalog lot. The paper’s authors declared no conflict of interest.[7] The formulation and excipient guide explains why material matching requires more than a shared name.
Tetrapeptide and extract-name boundary
Epitalon / Epithalon
Epitalon and Epithalon are spelling variants used for the Ala-Glu-Asp-Gly tetrapeptide. Epithalamin is a different pineal extract, not a synonym. Free base, acetate, and modified derivatives also require separate identification.[3]
The frequently cited telomere paper studied cultured human fetal fibroblasts.[8] Human-derived cells are not a human clinical trial. Cell-culture telomerase or telomere findings do not establish anti-aging, longevity, cancer prevention, or clinical safety in people.
FDA’s May 12, 2026 memorandum for the July 2026 meeting assessed Epitalon free base and acetate for insomnia. It did not evaluate every other nominated use. It discussed some human research, including a night-shift biomarker study, but noted that study did not measure sleep outcomes; it found insufficient evidence for insomnia and inadequate human safety information. This is not a claim that no human exposure study exists.[3] The memorandum is an advisory assessment, not product approval or a final compounding-list decision.
How to read CNS and neurobiology endpoints
| Endpoint or design | What it can show | What it cannot establish by itself |
|---|---|---|
| Gene expression or protein level | A molecular result in the tested system, including a null result | Improved cognition, mood, sleep, recovery, or disease outcome |
| Functional-connectivity imaging | A short-term imaging pattern | Clinical benefit or durable behavioral change |
| Animal ischemia or behavior model | A finding in the named species and model | Treatment effectiveness in people |
| Active-comparator study without placebo | A comparison under the tested conditions | Placebo-adjusted effect or therapeutic equivalence |
| Add-on study | An incremental comparison of combination versus background treatment, subject to bias controls | Monotherapy efficacy, synergy, or general benefit across other combinations |
| Null confirmatory endpoint | Failure to demonstrate the tested difference | Proof that every possible effect is exactly zero |
| Heterogeneous preparation | Evidence for the characterized preparation and assay | Equivalence of every product sold under a similar name |
The study-reading guide explains how to separate populations, comparators, primary outcomes, and exploratory analyses.
Why negative and mixed results belong on the hub
Outcome-led names can encourage selective reading. A search for a “sleep peptide” should still expose DSIP’s weak findings and unchanged subjective sleep quality. A search for a “stroke peptide” should not hide CASTA’s null primary endpoint. A search for a “longevity peptide” should not turn a fibroblast experiment into a human longevity trial.
The library treats those limits as findings. Secondary, subgroup, biomarker, and imaging results do not overwrite a null primary endpoint or missing confirmatory evidence. The negative and null results guide explains the difference between an unsuccessful comparison and proof of no possible effect.
Identity and regulatory boundaries
- Semax free base and Semax acetate are distinct materials.[1]
- FDA’s GSRS identifies Selank, but its identifier does not resolve every salt, counterion, formulation, or batch.[16]
- DSIP/emideltide’s name does not establish form, amount basis, or lot identity.[2]
- Cerebrolysin is a heterogeneous preparation, not a single peptide.[6,7]
- Epitalon/Epithalon is not Epithalamin.[3]
- A UNII is not approval; FDA product approval should be checked against the named product and its application.[9,16]
- Trial registration is not a favorable result or government endorsement.[10]
The sequence and structural identity guide and approved-drug versus research-material guide explain these distinct checks. The trial and FDA status guide covers date-sensitive records. This hub does not assert that a foreign authorization, advisory document, or study registration confers U.S. approval on a catalog substance.
Published compound records
Frequently asked questions
Does a brain-imaging change prove a cognitive or mood benefit?
No. Imaging is a surrogate measurement. A clinical-benefit claim needs direct evidence for the defined intervention, population, and relevant outcome.
Does the evidence reviewed here establish DSIP as an insomnia treatment?
No. The small controlled study described weak effects and unchanged subjective sleep quality; FDA’s dated assessment found the insomnia evidence inconclusive or preliminary.[2,5] This is an evidence conclusion for the sources reviewed, not a worldwide regulatory survey.
Is Cerebrolysin one peptide?
No. It is a heterogeneous biological preparation. Composition and process comparability are central to interpreting its studies.[6,7]
Does a study in cultured human neurons or fibroblasts count as a human trial?
No. Human-derived cells are laboratory models outside a living person. They cannot establish clinical longevity or treatment benefit on their own.
Does a ClinicalTrials.gov listing mean a CNS compound is approved?
No. NIH explains that listing does not mean a study has been evaluated by the U.S. federal government.[10] Product approval is a separate FDA question.[9]
Does this hub recommend a nootropic, sleep, anxiety, stroke, or longevity compound?
No. It organizes identity and evidence and provides no treatment or self-use recommendation.
Primary and official sources
- FDA, Semax memorandum, May 11, 2026; July 23–24 advisory materials
- FDA, emideltide memorandum, May 11, 2026; July 23–24 advisory materials
- FDA, Epitalon memorandum, May 12, 2026; July 23–24 advisory materials
- Semax and Selank functional-connectivity study, PMID 32342318
- DSIP double-blind chronic-insomnia study, PMID 1299794
- Cerebrolysin CASTA randomized trial, PMID 22282884
- Cerebrolysin preparation-comparison study, PMID 38737662; open published paper
- Epitalon human-fibroblast study, PMID 12937682
- FDA, Approved Drugs: Questions and Answers
- ClinicalTrials.gov, official disclaimer; NIH, Finding a Clinical Trial, listing limitations
- Selank IMR-32 cell-line gene-expression study, PMID 28293190
- Selank rat antenatal-hypoxia study, PMID 18197389
- Selank peripheral-blood-cell and patient cytokine study, PMID 18577961
- Selank active-comparator anxiety study, PMID 18454096
- Phenazepam versus phenazepam-plus-Selank study, PMID 26356395
- FDA GSRS, Selank, UNII TS9JR8EP1G
- ClinicalTrials.gov, CASTA, NCT00868283
Review and corrections
Sources checked September 2, 2026 (America/Edmonton) / September 3, 2026 (UTC). This is a selected, source-limited overview, not a systematic review. Most cited clinical and laboratory studies were checked through their indexed primary abstracts; the 2024 preparation-comparison paper was read in full. The FDA memoranda and current CASTA registry were checked directly. Complete trial protocols, statistical analysis plans, and participant-level data were not obtained; an abstract or advisory summary cannot replace those documents.
Serum Research takes editorial responsibility for this page. No independent scientific, clinical, statistical, analytical, or regulatory review is claimed. Editorial checking is not medical advice and does not establish catalog quality, authentication, safety, or equivalence. See how we review evidence and contact us with corrections. Return to the Research Library.